Nevertheless, BRCA1 carriers showed worse DFS, mostly due to higher rates of second primary malignancies (predominantly breast and ovarian cancers) as compared to BRCA2-mutated patients. This evidence concerns the gene BRCA2 and ovarian carcinoma.